These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22147526)

  • 21. Electrospray ionization-tandem mass spectrometry analysis of the mycolic acid profiles for the identification of common clinical isolates of mycobacterial species.
    Song SH; Park KU; Lee JH; Kim EC; Kim JQ; Song J
    J Microbiol Methods; 2009 May; 77(2):165-77. PubMed ID: 19318047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues.
    Polepole P; Kabwe M; Kasonde M; Tembo J; Shibemba A; O'Grady J; Kapata N; Zumla A; Bates M
    Int J Mycobacteriol; 2017; 6(1):87-93. PubMed ID: 28317811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The mycolic acids analysis with HPLC technique in drug susceptibility testing of Mycobacterium tuberculosis strains].
    Walkiewicz R; Grubek-Jaworska H; Chazan R
    Pneumonol Alergol Pol; 2006; 74(1):89-94. PubMed ID: 17175985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.
    Boehme CC; Nicol MP; Nabeta P; Michael JS; Gotuzzo E; Tahirli R; Gler MT; Blakemore R; Worodria W; Gray C; Huang L; Caceres T; Mehdiyev R; Raymond L; Whitelaw A; Sagadevan K; Alexander H; Albert H; Cobelens F; Cox H; Alland D; Perkins MD
    Lancet; 2011 Apr; 377(9776):1495-505. PubMed ID: 21507477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.
    Wallis RS; Phillips M; Johnson JL; Teixeira L; Rocha LM; Maciel E; Rose L; Wells C; Palaci M; Dietze R; Eisenach K; Ellner JJ
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1302-4. PubMed ID: 11257053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.
    Wake RM; Poulikakos P; Groth J; Harrison TS; Macallan DC
    Int J STD AIDS; 2013 Apr; 24(4):263-8. PubMed ID: 23635810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration.
    Johnson JL; Vjecha MJ; Okwera A; Hatanga E; Byekwaso F; Wolski K; Aisu T; Whalen CC; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1998 May; 2(5):397-404. PubMed ID: 9613636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standardization of natural mycolic acid antigen composition and production for use in biomarker antibody detection to diagnose active tuberculosis.
    Ndlandla FL; Ejoh V; Stoltz AC; Naicker B; Cromarty AD; van Wyngaardt S; Khati M; Rotherham LS; Lemmer Y; Niebuhr J; Baumeister CR; Al Dulayymi JR; Swai H; Baird MS; Verschoor JA
    J Immunol Methods; 2016 Aug; 435():50-9. PubMed ID: 27247168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture.
    Bakari M; Arbeit RD; Mtei L; Lyimo J; Waddell R; Matee M; Cole BF; Tvaroha S; Horsburgh CR; Soini H; Pallangyo K; von Reyn CF
    BMC Infect Dis; 2008 Mar; 8():32. PubMed ID: 18325120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    Manosuthi W; Kiertiburanakul S; Sungkanuparph S; Ruxrungtham K; Vibhagool A; Rattanasiri S; Thakkinstian A
    AIDS; 2006 Jan; 20(1):131-2. PubMed ID: 16327334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa.
    Rambaran S; Naidoo K; Lewis L; Hassan-Moosa R; Govender D; Samsunder N; Scriba TJ; Padayatchi N; Sivro A
    Front Immunol; 2021; 12():641065. PubMed ID: 33868272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.
    Durovni B; Saraceni V; van den Hof S; Trajman A; Cordeiro-Santos M; Cavalcante S; Menezes A; Cobelens F
    PLoS Med; 2014 Dec; 11(12):e1001766. PubMed ID: 25490549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
    Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of mycolic acids in different mycobacterial species by standard addition method through liquid chromatography mass spectrometry.
    Fatima Z; Chugh M; Nigam G; Hameed S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Oct; 1247():124297. PubMed ID: 39299149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis.
    Garza-González E; Guerrero-Olazarán M; Tijerina-Menchaca R; Viader-Salvadó JM
    J Clin Microbiol; 1997 May; 35(5):1287-9. PubMed ID: 9114429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and performance of CUHAS-ROBUST application for pulmonary rifampicin-resistance tuberculosis screening in Indonesia.
    Herman B; Sirichokchatchawan W; Pongpanich S; Nantasenamat C
    PLoS One; 2021; 16(3):e0249243. PubMed ID: 33765092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-function relationships of the antigenicity of mycolic acids in tuberculosis patients.
    Beukes M; Lemmer Y; Deysel M; Al Dulayymi JR; Baird MS; Koza G; Iglesias MM; Rowles RR; Theunissen C; Grooten J; Toschi G; Roberts VV; Pilcher L; Van Wyngaardt S; Mathebula N; Balogun M; Stoltz AC; Verschoor JA
    Chem Phys Lipids; 2010 Nov; 163(8):800-8. PubMed ID: 20875402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.